Expertise Partner

Retrogenix advances medical research and speeds up drug discovery for its clients by providing a unique service which identifies specific cell surface protein interactions in human cells. Retrogenix now has research agreements with fourteen of the top fifteen global pharmaceutical companies, numerous drug discovery companies and many leading academic and non-for-profit institutions around the world.

GE Healthcare

Expertise Partner

Cell and gene therapies are quickly reaching an inflection point, showing great promise for the future of patient care. At GE Healthcare’s Cell Therapy Technologies, we strive to be at the forefront of this revolution by providing the right combination of customized tools, analytics, and support, while helping to standardize and optimize scale-out manufacturing technologies. Together we hope to realize the promise of these revolutionary new medicines and bring them into mainstream clinical use.

Irvine Scientific

Fujifilm Irvine

Hosting Partner

FUJIFILM Irvine Scientific is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 45 years FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.




CellGenix is a premium supplier of high-quality reagents and tools for cell therapy applications. Our mission is to enable and accelerate safe and efficient transition of cell, gene and tissue engineered products from preclinical to post-approval clinical applications for the benefit of patients worldwide.